Table 1 Baseline characteristics of patients in different treatment groups

Age (years; median)

39 (13–68)

34 (23–62)

Sex (female) (number)

16 (41%)

5 (35.7%)

BMI (median)

25.7 (18.3–37.2)

27.1 (19.8–51.4)

Date from symptom onset (median) (day)

10 (1–365)

17 (2–100)

Venous sinus involved (> 1 segment)

33 (84.6%)

14 (100%)

History of cysteinemia (number)

12 (30.7%)

5 (35.7%)

History of contraceptive usage (number)

3 (7.7%)

1 (7.1%)

History of hypertension (number)

9 (23%)

2 (14.3%)

History of dyslipidemia (number)

16 (41%)

7 (50%)

History of blood coagulation disfunction (number)

14 (35.9%)

5 (35.7%)

Smoking (number)

8 (20.5%)

9 (64.3%)

Accompany with cerebral hemorrhage (number)

11 (28.2%)

4 (28.6%)

Accompany with cerebral venous infarction (number)

9 (23.1%)

4 (28.6%)

ICP (> 200 mmH₂O) (number)

19 (61.3%)

10 (90.9%)

Coagulation function (proper value)

Fibrin degradation product (µg/mL)

2.84 (0.34–15.13)

2.3 (0.7–19.2)

D-Dimer (µg/mL)

1 (0.05–9.88)

1.04 (0.39–10.38)

Prothrombin time (INR)

1.08 (0.92–3.73)

1 (0.92–4.37)

Activated partial thromboplastin time (s)

29.6 (16.6–54.4)

28.5 (24.4–46.5)

Thrombin time (s)

14 (11.5–17.8)

13.9 (11.7–16.6)

Fibrinogen (g/L)

3.48 (2.09–5.47)

3.47 (2.14–4.87)

Platelet (10⁹/L)

244 (99–612)

232 (180–345)

Platelet distribution width (fL)

15.9 (15.3–17.2)

16 (15.5–16.5)

Mean platelet volume (fL)

9.1 (7.3–10.5)

8.7 (7.7–10.6)

Platelet - larger cell ratio

20.4 (9.4–30.6)

16.7 (11.2–31.6)